LGALS1 and hepatocellular carcinoma: Interestingly, SGT-53 treatment significantly increased miR-22 (Figure 6E), which has been shown to inhibit the expression of Gal-1 in hepatocellular carcinoma and renal cell carcinoma [22,23].